Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...

Actively engaged with Terumo in Virtue SAB partnership restructuring discussions.

UPMC Heart and Vascular Institute in central Pennsylvania has treated its first patient with a new therapy.

UPMC Offers New Heart Treatment for Stent Patients UPMC Heart and Vascular Institute in Central Pa. has treated its first patient with a new therapy for in-stent restenosis (ISR), a condition in which ...

TCT 320: Dynamic Coronary Roadmap in Occluded Vessel Angioplasty in STEMI: Does It Still Reduce the Contrast Load: A Randomized Trial Subanalysis Receive the the latest news, research, and ...

In another study, the sirolimus-eluting stent was implanted in 16 patients with severe, recurrent ISR in a native coronary artery. [27] At four months, angiographic and IVUS analysis was performed ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Benjamin Netanyahu, Israel's prime minister, during the United Nations General Assembly in New York on Sept. 27, 2024. Photo: Jeenah Moon/Bloomberg via Getty Images Smarter, faster on what matters.

The diagnosis of ISR was made on coronary angiography. Patients were eligible for inclusion in the registry if they met the following criteria: (1) chronic or acute coronary syndrome (excluding ...

to commence a pivotal clinical trial for its Prevail coronary paclitaxel drug-coated balloon (DCB). This trial is aimed at treating in-stent restenosis (ISR) and de novo small vessel disease.

The medtech giant can now begin a pivotal clinical trial for the coronary paclitaxel DCB for in-stent restenosis (ISR) and de novo small vessel disease. It plans to use data from its Prevail Global ...